Icosapent ethyl for the treatment of severe hypertriglyceridemia

References

• PejicRNLeeDTHypertriglyceridemiaJ Am Board Fam Med200619331031616672684
   PubMed Web of Science ®Google Scholar
• SandhuSAl-SarrafATaraboantaCFrohlichJFrancisGAIncidence of pancreatitis, secondary causes, and treatment of patients referred to a specialty lipid clinic with severe hypertriglyceridemia: a retrospective cohort studyLipids Health Dis20111015721906399
   PubMed Web of Science ®Google Scholar
• ChristianJBBourgeoisNSnipesRLoweKAPrevalence of severe (500 to 2,000 mg/dL) hypertriglyceridemia in United States adultsAm J Cardiol2011107689189721247544
   PubMed Web of Science ®Google Scholar
• SchererJSinghVPPitchumoniCSYadavDIssues in hypertriglyceridemic pancreatitis: an updateJ Clin Gastroenterol201448319520324172179
   PubMed Web of Science ®Google Scholar
• GandotraPMillerMThe role of triglycerides in cardiovascular riskCurr Cardiol Rep200810650551118950562
   PubMedGoogle Scholar
• The EPA Drug Initiative [webpage on the Internet]FDA puts patients at risk, now says lowering triglycerides will not protect from heart attack and stroke2013 Available from: http://epadruginitiative.com/press/fda-puts-patients-at-riskAccessed February 13, 2014
   Google Scholar
• BallantyneCMBaysHEKasteleinJJEfficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study)Am J Cardiol2012110798499222819432
   PubMed Web of Science ®Google Scholar
• MillerMStoneNJBallantyneCAmerican Heart Association Clinical Lipidology, Thrombosis, and Prevention Committee of the Council on Nutrition, Physical Activity, and MetabolismCouncil on Arteriosclerosis, Thrombosis and Vascular BiologyCouncil on Cardiovascular NursingCouncil on the Kidney in Cardiovascular DiseaseTriglycerides and cardiovascular disease: a scientific statement from the American Heart AssociationCirculation2011123202292233321502576
   PubMed Web of Science ®Google Scholar
• OhRCLanierJBManagement of hypertriglyceridemiaAm Fam Physician20077591365137117508532
   PubMed Web of Science ®Google Scholar
• LavieCJMilaniRVMehraMRVenturaHOOmega-3 polyunsaturated fatty acids and cardiovascular diseasesJ Am Coll Cardiol200954758559419660687
   PubMed Web of Science ®Google Scholar
• LeeJHO’KeefeJHLavieCJMarchioliRHarrisWSOmega-3 fatty acids for cardioprotectionMayo Clin Proc200883332433218316000
   PubMed Web of Science ®Google Scholar
• PereiraSLLeonardAEHuangYSChuangLTMukerjiPIdentification of two novel microalgal enzymes involved in the conversion of the omega3-fatty acid, eicosapentaenoic acid, into docosahexaenoic acidBiochem J2004384Pt 235736615307817
   PubMedGoogle Scholar
• BallantyneCMBraeckmanRASoniPNIcosapent ethyl for the treatment of hypertriglyceridemiaExpert Opin Pharmacother201314101409141623701295
   PubMed Web of Science ®Google Scholar
• MasoroEJLipids and lipid metabolismAnnu Rev Physiol197739301321192136
   PubMed Web of Science ®Google Scholar
• WilhelmMGCooperADInduction of atherosclerosis by human chylomicron remnants: a hypothesisJ Atheroscler Thromb200310313213914564081
   PubMedGoogle Scholar
• DunbarRLRaderDJDemystifying triglycerides: a practical approach for the clinicianCleve Clin J Med2005728661666670672 674–675 passim16122052
   PubMed Web of Science ®Google Scholar
• ShearerGCSavinovaOVHarrisWSFish oil – how does it reduce plasma triglycerides?Biochim Biophys Acta20121821584385122041134
   PubMed Web of Science ®Google Scholar
• HarrisWSBulchandaniDWhy do omega-3 fatty acids lower serum triglycerides?Curr Opin Lipidol200617438739316832161
   PubMed Web of Science ®Google Scholar
• QiKFanCJiangJOmega-3 fatty acid containing diets decrease plasma triglyceride concentrations in mice by reducing endogenous triglyceride synthesis and enhancing the blood clearance of triglyceride-rich particlesClin Nutr200827342443018362042
   PubMed Web of Science ®Google Scholar
• CalderPCMechanisms of action of (n-3) fatty acidsJ Nutr20121423592S599S22279140
   PubMed Web of Science ®Google Scholar
• SchoonjansKStaelsBAuwerxJThe peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiationBiochim Biophys Acta199613022931098695669
   PubMed Web of Science ®Google Scholar
• SzantoANagyLThe many faces of PPARgamma: anti-inflammatory by any means?Immunobiology20082139–1078980318926294
   PubMed Web of Science ®Google Scholar
• DavidsonMHMechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acidsAm J Cardiol2006984A27i33i
   PubMed Web of Science ®Google Scholar
• HarrisWSn-3 fatty acids and serum lipoproteins: animal studiesAm J Clin Nutr199765Suppl 51611S1616S9129501
   PubMed Web of Science ®Google Scholar
• LawsonLDHughesBGAbsorption of eicosapentaenoic acid and docosahexaenoic acid from fish oil triacylglycerols or fish oil ethyl esters co-ingested with a high-fat mealBiochem Biophys Res Commun198815629609632847723
   PubMed Web of Science ®Google Scholar
• LawsonLDHughesBGHuman absorption of fish oil fatty acids as triacylglycerols, free acids, or ethyl estersBiochem Biophys Res Commun198815213283353358766
   PubMed Web of Science ®Google Scholar
• BeckermannBBenekeMSeitzIComparative bioavailability of eicosapentaenoic acid and docasahexaenoic acid from triglycerides, free fatty acids and ethyl esters in volunteersArzneimittelforschung1990406700704 German2144420
   PubMed Web of Science ®Google Scholar
• JacobsonTAA new pure ω-3 eicosapentaenoic acid ethyl ester (AMR101) for the management of hypertriglyceridemia: the MARINE trialExpert Rev Cardiovasc Ther201210668769522894624
   PubMedGoogle Scholar
• BaysHEBraeckmanRABallantyneCMIcosapent ethyl, a pure EPA omega-3 fatty acid: effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study)J Clin Lipidol20126656557223312052
   PubMed Web of Science ®Google Scholar
• HarrisWSDayspringTDMoranTJOmega-3 fatty acids and cardiovascular disease: new developments and applicationsPostgrad Med2013125610011324200766
   PubMed Web of Science ®Google Scholar
• WeiMYJacobsonTAEffects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids: a systematic review and meta-analysisCurr Atheroscler Rep201113647448321975919
   PubMed Web of Science ®Google Scholar
• JacobsonTAGlicksteinSBRoweJDSoniPNEffects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a reviewJ Clin Lipidol20126151822264569
   PubMed Web of Science ®Google Scholar
• MakiKCLawlessALKelleyKMEffects of prescription omega-3-acid ethyl esters on fasting lipid profile in subjects with primary hypercholesterolemiaJ Cardiovasc Pharmacol201157448949421297494
   PubMed Web of Science ®Google Scholar
• NestelPShigeHPomeroySCehunMAbbeyMRaederstorffDThe n-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid increase systemic arterial compliance in humansAm J Clin Nutr200276232633012145002
   PubMed Web of Science ®Google Scholar
• GlasserSPArnettDKMcVeighGEVascular compliance and cardiovascular disease: a risk factor or a marker?Am J Hypertens19971010 Pt 1117511899370391
   PubMed Web of Science ®Google Scholar
• DrüekeTBNguyen KhoaTMassyZAWitko-SarsatVLacourBDescamps-LatschaBRole of oxidized low-density lipoprotein in the atherosclerosis of uremiaKidney Int Suppl200178S114S11911168995
   PubMedGoogle Scholar
• AndoMSanakaTNiheiHEicosapentanoic acid reduces plasma levels of remnant lipoproteins and prevents in vivo peroxidation of LDL in dialysis patientsJ Am Soc Nephrol199910102177218410505695
   PubMed Web of Science ®Google Scholar
• DavidsonMHSteinEABaysHECOMBination of prescription Omega-3 with Simvastatin (COMBOS) InvestigatorsEfficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled studyClin Ther20072971354136717825687
   PubMed Web of Science ®Google Scholar